BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29103769)

  • 1. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
    Wang L; Li Z; Liu C; Chen L; Liu L; Hu Z; Zhao L; Lu D; Teng L
    Pathol Res Pract; 2017 Dec; 213(12):1489-1493. PubMed ID: 29103769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma.
    Li M; Dong G; Zhang W; Ren X; Jiang H; Yang C; Zhao X; Zhu Q; Li M; Chen H; Yu K; Cui Y; Song L
    Cancer Sci; 2021 Sep; 112(9):3699-3710. PubMed ID: 34115910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
    Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients.
    Hsu CY; Ho HL; Lin SC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):497-504. PubMed ID: 27153440
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Johannessen LE; Brandal P; Myklebust TÅ; Heim S; Micci F; Panagopoulos I
    Cancer Genomics Proteomics; 2018; 15(6):437-446. PubMed ID: 30343277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
    McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
    Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M
    PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
    Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
    J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.
    Trabelsi S; Mama N; Ladib M; Karmeni N; Haddaji Mastouri M; Chourabi M; Mokni M; Tlili K; Krifa H; Yacoubi MT; Saad A; H'mida Ben Brahim D
    Clin Transl Oncol; 2016 Apr; 18(4):391-7. PubMed ID: 26289551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
    Tzaridis T; Schäfer N; Weller J; Steinbach JP; Schlegel U; Seidel S; Sabel M; Hau P; Seidel C; Krex D; Goldbrunner R; Tonn JC; Grauer O; Kebir S; Schneider M; Schaub C; Vatter H; Coch C; Glas M; Fimmers R; Pietsch T; Reifenberger G; Herrlinger U; Felsberg J
    Int J Cancer; 2021 Apr; 148(7):1695-1707. PubMed ID: 33113214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
    Balańa C; Carrato C; Ramírez JL; Cardona AF; Berdiel M; Sánchez JJ; Tarón M; Hostalot C; Musulen E; Ariza A; Rosell R
    Clin Transl Oncol; 2011 Sep; 13(9):677-85. PubMed ID: 21865140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive markers for MGMT promoter methylation in glioblastomas.
    Kanazawa T; Minami Y; Jinzaki M; Toda M; Yoshida K; Sasaki H
    Neurosurg Rev; 2019 Dec; 42(4):867-876. PubMed ID: 30673883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.